X-Chem has been leading the DNA-encoded library (DEL) field for more than a decade. We have delivered over 90 programs to our partners and clients, comprising over 1,000 novel, validated hit compounds across more than 30 different target classes. Most of these projects are actively progressed by our clients and remain confidential, but examples have been published in peer-reviewed journals. We have compiled these examples into the list below: They span a wide variety of therapy areas and target classes. Some represent our older and more peptidic libraries and others exemplify more contemporary and lead-like library designs. We continue to be at the forefront of DEL development, incorporating AI in drug discovery to explore greater chemical space .
Click below to take a tour through X-Chem’s track record of success.
Published Successes From X-Chem and Our Partners
Enzymes
Target:
SARS-CoV-2, Mpro IC50 = 6 nM, antiviral EC50 33 nM
Therapy Area:
Antiviral
Target:
SARS-CoV-2, Mpro IC50 = 6 nM, antiviral EC50 33 nM
Molecular Weight:
587
CLogP:
2.6
LE:
0.29
LLE:
5.6
Therapy Area:
Antiviral
Category of Compound:
Non-Covalent Lead Series Member
Protein Protein Interaction
Target:
Bfl1, IC50 = 4.3μM
Therapy Area:
Oncology
Target:
Bfl1, IC50 = 4.3μM
Molecular Weight:
446.4
CLogP:
4.50
LE:
0.235
LLE:
0.86
Therapy Area:
Oncology
Category of Compound:
Improved Reversible Covalent Hit
Enzymes
Target:
Pks13, MIC = 250 nM
Therapy Area:
Infectious Disease
Target:
Pks13, MIC = 250 nM
Molecular Weight:
457.5
CLogP:
3.86
LE:
0.26
LLE:
2.74
Therapy Area:
Infectious Disease
Category of Compound:
Lead
Protein Protein Interaction
Target:
IL-17A, HeLa IC50 = 5 nM
Therapy Area:
Inflammation
Target:
IL-17A, HeLa IC50 = 5 nM
Molecular Weight:
612.6
CLogP:
0.67
LE:
0.27
LLE:
6.34
Therapy Area:
Inflammation
Category of Compound:
Advanced Lead
Protein Protein Interaction
Target:
Mcl-1, IC50 = 31 nM
Therapy Area:
Oncology
Target:
Mcl-1, IC50 = 31 nM
Molecular Weight:
925.4
CLogP:
3.4
LE:
0.16
LLE:
2.0
Therapy Area:
Oncology
Category of Compound:
Lead Candidate
Receptors
Target:
ERa Degrader, DC50 = 37 nM
Therapy Area:
Oncology
Target:
ERa Degrader, DC50 = 37 nM
Therapy Area:
Oncology
Category of Compound:
Lead Degrader
Protein Protein Interaction
Target:
WDR91, Kd = 6µM
Therapy Area:
Virology
Target:
WDR91, Kd = 6µM
Molecular Weight:
372.9
CLogP:
2.6
LE:
0.28
LipE:
2.6
Therapy Area:
Virology
Category of Compound:
Tool Compound
Protein Protein Interaction
Target:
DCAF1, SPR KD = 38 nM
Therapy Area:
Oncology
Target:
DCAF1, SPR KD = 38 nM
Molecular Weight:
439.24
CLogP:
3.57
LE:
0.35
LLE:
3.39
Therapy Area:
Oncology
Category of Compound:
Improved Hit
Kinases
cMet mutant, IC50 = 90 nM
Target:
cMet mutant, IC50 = 90 nM
Therapy Area:
Oncology
Target:
cMet mutant, IC50 = 90 nM
Molecular Weight:
460.5
CLogP:
5.0
LE:
0.29
LipE:
2.0
Therapy Area:
Oncology
Category of Compound:
Screening Hit
Enzymes
LpxA Inhibitor, IC50= 19 nM
Target:
LpxA Inhibitor, IC50 = 19 nM
Therapy Area:
Infectious Disease
Target:
LpxA Inhibitor, IC50 = 19 nM
Molecular Weight:
413.88
CLogP:
1.80
LE:
0.39
LipE:
5.9
Therapy Area:
Infectious Disease
Category of Compound:
Improved Hit
Enzymes
HAO1 Inhibitor, IC50= 25 nM
Target:
HAO1 Inhibitor, IC50 = 25 nM
Therapy Area:
Rare Disease
Target:
HAO1 Inhibitor, IC50 = 25 nM
Molecular Weight:
394.45
CLogP:
3.84
LE:
0.37
LipE:
3.8
Therapy Area:
Rare Disease:primary hyperoxaluria
Category of Compound:
Improved Hit
Receptors
Target:
ERa Binder, IC50 = 50 nM
Therapy Area:
Oncology
Target:
ERa Binder, IC50 = 50 nM
Molecular Weight:
321.77
CLogP:
4.65
LE:
0.49
LipE:
2.7
Therapy Area:
Oncology
Category of Compound:
Screening Hit
Receptors
PAR2 Antagonist, IC50= 23 nM
Target:
PAR2 Antagonist, IC50 = 23 nM
Therapy Area:
Neurology
Target:
PAR2 Antagonist, IC50 = 23 nM
Molecular Weight:
571.48
CLogP:
7.96
LE:
0.29
LipE:
-0.32
Therapy Area:
Neurology
Category of Compound:
Improved Hit
Receptors
PAR2 Agonist, EC50= 230 nM
Target:
PAR2 Agonist, EC50 = 230 nM
Therapy Area:
Neurology
Target:
PAR2 Agonist, EC50 = 230 nM
Molecular Weight:
542.68
CLogP:
3.39
LE:
0.23
LipE:
3.3
Therapy Area:
Neurology
Category of Compound:
Screening Hit
Enzymes
ATX Inhibitor, IC50= 55 nM
Target:
ATX Inhibitor, IC50 = 55 nM
Therapy Area:
Inflammation
Target:
ATX Inhibitor, IC50 = 55 nM
Molecular Weight:
588.56
CLogP:
2.68
LE:
0.24
LipE:
4.6
Therapy Area:
Inflammation
Category of Compound:
Clinical Candidate
Kinases
TAK1 Inhibitor, IC50= 5 nM
Target:
TAK1 Inhibitor, IC50 = 5 nM
Therapy Area:
Oncology
Target:
TAK1 Inhibitor, IC50 = 5 nM
Molecular Weight:
526.5
CLogP:
0.10
LE:
0.31
LipE:
8.2
Therapy Area:
Oncology
Category of Compound:
Improved Hit
Enzymes
sEH Inhibitor, IC50= 2 nM
Target:
sEH Inhibitor, IC50 = 2 nM
Therapy Area:
Inflammation
Target:
sEH Inhibitor, IC50 = 2 nM
Molecular Weight:
430.55
CLogP:
4.36
LE:
0.38
LipE:
4.33
Therapy Area:
Inflammation
Category of Compound:
Screening Hit
Kinases
BTK Inhibitor, IC50= 2 nM
Target:
BTK Inhibitor, IC50 = 2 nM
Therapy Area:
Oncology
Target:
BTK Inhibitor, IC50 = 2 nM
Molecular Weight:
480.53
CLogP:
2.34
LE:
0.34
LipE:
6.36
Therapy Area:
Oncology
Category of Compound:
Screening Hit
Kinases
BTK Inhibitor, IC50= 60 nM (1h)
Target:
BTK Inhibitor, IC50 = 60 nM (1h)
Therapy Area:
Oncology
Target:
BTK Inhibitor, IC50 = 60 nM (1h)
Molecular Weight:
444.53
CLogP:
1.95
Therapy Area:
Oncology
Category of Compound:
Covalent Screening Hit
Kinases
MerTK Inhibitor, IC50= 5 nM
Target:
MerTK Inhibitor, IC50 = 5 nM
Therapy Area:
Oncology
Target:
MerTK Inhibitor, IC50 = 5 nM
Molecular Weight:
415.88
CLogP:
5.06
LE:
0.39
LipE:
3.24
Therapy Area:
Oncology
Category of Compound:
Screening Hit
Enzymes
KMO Inhibitor, IC50= 14 nM
Target:
KMO Inhibitor, IC50 = 14 nM
Therapy Area:
Oncology
Target:
KMO Inhibitor, IC50 = 14 nM
Molecular Weight:
496.33
CLogP:
5.41
LE:
0.34
LipE:
2.44
Therapy Area:
Oncology
Category of Compound:
Screening Hit
Protein Protein Interaction
ATAD2 Inhibitor, IC50= 25 nM
Target:
ATAD2 Inhibitor, IC50 = 25 nM
Therapy Area:
Oncology
Target:
ATAD2 Inhibitor, IC50 = 25 nM
Molecular Weight:
640.23
CLogP:
3.80
LE:
0.23
LipE:
3.8
Therapy Area:
Oncology
Protein Protein Interaction
Mcl-1 Inhibitor, IC50= <3 nM
Target:
Mcl-1 Inhibitor, IC50 = <3 nM
Therapy Area:
Oncology
Target:
Mcl-1 Inhibitor, IC50 = <3 nM
Molecular Weight:
826.45
CLogP:
6.56
LE:
0.21
LipE:
1.96
Therapy Area:
Oncology
Category of Compound:
Improved Hit
Enzymes
InhA Inhibitor, IC50 = 26 nM
Target:
InhA Inhibitor, IC50 = 26 nM
Therapy Area:
Tuberculosis
Target:
InhA Inhibitor, IC50 = 26 nM
Molecular Weight:
487.68
CLogP:
3.10
LE:
0.32
LipE:
4.48
Therapy Area:
Tuberculosis
Category of Compound:
Screening Hit